Cover Image
Market Research Report

Hemophilia A - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 232826
Published Content info 186 Pages
Delivery time: 1-2 business days
Price
Back to Top
Hemophilia A - Pipeline Review, H2 2018
Published: November 13, 2018 Content info: 186 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2018, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 9, 2, 2, 26, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11006IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Hemophilia A - Overview
  • Hemophilia A - Therapeutics Development
  • Hemophilia A - Therapeutics Assessment
  • Hemophilia A - Companies Involved in Therapeutics Development
  • Hemophilia A - Drug Profiles
  • Hemophilia A - Dormant Projects
  • Hemophilia A - Discontinued Products
  • Hemophilia A - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hemophilia A, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Hemophilia A - Pipeline by Amarna Therapeutics BV, H2 2018
  • Hemophilia A - Pipeline by Apitope International NV, H2 2018
  • Hemophilia A - Pipeline by Bayer AG, H2 2018
  • Hemophilia A - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2018
  • Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H2 2018
  • Hemophilia A - Pipeline by Bioverativ Inc, H2 2018
  • Hemophilia A - Pipeline by Casebia Therapeutics, H2 2018
  • Hemophilia A - Pipeline by Catalyst Biosciences Inc, H2 2018
  • Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
  • Hemophilia A - Pipeline by CSL Ltd, H2 2018
  • Hemophilia A - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Hemophilia A - Pipeline by DBV Technologies SA, H2 2018
  • Hemophilia A - Pipeline by EpiVax Inc, H2 2018
  • Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2018
  • Hemophilia A - Pipeline by GC Pharma, H2 2018
  • Hemophilia A - Pipeline by ID Pharma Co Ltd, H2 2018
  • Hemophilia A - Pipeline by Idogen AB, H2 2018
  • Hemophilia A - Pipeline by Immusoft Corp, H2 2018
  • Hemophilia A - Pipeline by Innovare R & D SA De CV, H2 2018
  • Hemophilia A - Pipeline by LFB SA, H2 2018
  • Hemophilia A - Pipeline by Novo Nordisk AS, H2 2018
  • Hemophilia A - Pipeline by Octapharma AG, H2 2018
  • Hemophilia A - Pipeline by Okklo Life Sciences BV, H2 2018
  • Hemophilia A - Pipeline by OPKO Biologics Ltd, H2 2018
  • Hemophilia A - Pipeline by Pangen Biotech Inc., H2 2018
  • Hemophilia A - Pipeline by Pfizer Inc, H2 2018
  • Hemophilia A - Pipeline by Pharming Group NV, H2 2018
  • Hemophilia A - Pipeline by Promethera Biosciences SA, H2 2018
  • Hemophilia A - Pipeline by Recursion Pharmaceuticals Inc, H2 2018
  • Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H2 2018
  • Hemophilia A - Pipeline by Sanofi, H2 2018
  • Hemophilia A - Pipeline by Shire Plc, H2 2018
  • Hemophilia A - Pipeline by Sino Biopharmaceutical Ltd, H2 2018
  • Hemophilia A - Pipeline by SK Chemicals Co Ltd, H2 2018
  • Hemophilia A - Pipeline by Spark Therapeutics Inc, H2 2018
  • Hemophilia A - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018
  • Hemophilia A - Pipeline by UniQure NV, H2 2018
  • Hemophilia A - Pipeline by XL-protein GmbH, H2 2018
  • Hemophilia A - Dormant Projects, H2 2018
  • Hemophilia A - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Hemophilia A, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018
Back to Top